Rapport Therapeutics is a clinical-stage biopharmaceutical company developing precision small-molecule medicines for central nervous system disorders. Its lead candidate, RAP-219, is designed to selectively inhibit TARPγ8-containing AMPA receptors and is being studied for focal epilepsy, with potential extensions into neuropathic pain and bipolar disorder. The pipeline also includes nicotinic acetylcholine receptor programs aimed at chronic pain, migraine, and hearing or vestibular conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -24.1 | — |
| Q2 2025 | 0 | — | -26.7 | — |
| Q3 2025 | 0 | — | -26.9 | — |
| Q4 2025 | 0 | — | -33.8 | — |
| Q1 2026 | 20 | — | -19.9 | — |
| Q2 2026 | 0 | — | -56.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Inhibrx Biosciences, Inc. (INBX), Peoples Bancorp Inc. (PEBO), HBT Financial, Inc. (HBT), Perella Weinberg Partners (PWP), Afya Limited (AFYA), Elemental Royalty Corporation (ELE)